TGFB1 and neoplasm: A recent study by Torrens and colleagues found that in addition to inhibiting angiogenesis in tumor tissues, combined Lenvatinib with pembrolizumab exerted distinct immunomodulatory effects by stimulating immunological pathways, decreasing Treg cell infiltration, and blocking TGF-β signaling (17).